Eugene

[email protected]

LATEST

Teva Ends Migraine-Drug Pact with Heptares
By

By
Sosei Group, a Tokyo, Japan-headquartered biopharmaceutical company, has regained worldwide rights from Teva Pharmaceutical Industries to develop and commercialize Sosei’s lead calcitonin gene-related peptide (CGRP) drug candidate and other small…

FDA Approves First Two Generics of Amgen’s Blockbuster Drug Sensipar
By

By
The US Food and Drug Administration (FDA) has approved two generic versions of Amgen’s Sensipar (cinacalcet hydrochloride), a calcium-reducer and one of its top-selling drugs, to Aurobindo Pharma, a Hyderabad,…

Recipharm Completes $22-Million Blow–Fill–Seal Tech Expansion
By

By
Recipharm, a Jordbro, Sweden-based CDMO, has reported that a $22-million blow-fill-seal filling and packaging line is now operational at its facility in Kaysersberg, France. The EUR 18 million ($22 million)…

FDA Requests Additional Info on Hikma’s Generic of GSK Respiratory Drug
By

By
Hikma Pharmaceuticals reports that it is has received a response from the US Food and Drug Administration (FDA) in relation to its abbreviated new drug application for its generic version…

Biogen To Buy Pfizer Schizophrenia Drug in $590-Million Deal
By

By
Biogen has agreed to acquire from Pfizer a drug to treat cognitive impairment associated with schizophrenia in a deal worth up to $590 million. The purchase will include an upfront…

Novartis’ CEO Makes New Appointments to Executive Team
By

By
Novartis has announced changes to its senior leadership team to support the implementation of its strategic priorities as well as a change in structure to its business operations. Bertrand Bodson,…

Ex-GSK CEO Andrew Witty to Become Optum CEO
By

By
Andrew Witty, formerly chief executive officer (CEO) of GlaxoSmithKline (GSK), will become CEO of Optum, the health services company of the health insurer, UnitedHealth Group, effective July 1, 2018. Witty…

DowDuPont Chairman Andrew Liveris to Step Down
By

By
DowDuPont, the combined company of the merger of The Dow Chemical Company and DuPont, has announced that Andrew N. Liveris is stepping down from his role as executive chairman, effective…

MedPharm Invests $75 Million in Automated Testing Equipment
By

By
MedPharm, a Guildford, England-headquartered provider of formulation and development services for topical and transdermal products, has invested $75 million on automated instrumentation for its US facilities based in Durham, North…

Charles River Labs Adds New Facility for Biologics Testing
By

By
Charles River Laboratories, a Wilmington, Massachusetts-headquartered contract research organization (CRO), has added a new, 73,000-square-foot facility in Wayne, Pennsylvania to expand its biologics testing services. Charles River announced several expansions…